NASDAQ: ANIXAnixa Biosciences Inc Stock
$2.48+0.13 (+5.53%)
Updated Jun 11, 2026
ANIX Price
$2.48
Fair Value Price
$0.03
Market Cap
$84.38M
52 Week Low
$2.32
52 Week High
$5.46
P/E
-8x
P/B
5.83x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.03M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$7M
Beta
1.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ANIX Overview
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ANIX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ANIX
Ranked#279 of 463
Ranked#279 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important ANIX news, forecast changes, insider trades & much more!
ANIX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ANIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANIX ($2.48) is overvalued by 7,639.03% relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ANIX ($2.48) is not significantly undervalued (7,639.03%) relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ANIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ANIX due diligence checks available for Premium users.
Valuation
ANIX fair value
Fair Value of ANIX stock based on Discounted Cash Flow (DCF)
Price
$2.48
Fair Value
$0.03
Overvalued by
7,639.03%
ANIX ($2.48) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANIX ($2.48) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ANIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANIX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8x
Industry
17.66x
Market
13.95x
ANIX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.83x
Industry
4.83x
ANIX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANIX's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.5M
Profit Margin
0%
ANIX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$14.9M
Liabilities
$1.6M
Debt to equity
0.11
ANIX's short-term assets ($14.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANIX's short-term assets ($14.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANIX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ANIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.7M
Investing
$422.0k
Financing
$1.2M
ANIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANIX vs Biotech Stocks
Anixa Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.